 The authors provide their opinion about the old and novel therapeutic strategy in non metastatic TNBC. The trial is well analysed and commented; however, the manuscript requires some improvement of English. In the context of novel option, the authors should discuss the negative results of neoadiuvant GEpar nuevo study, presented at ASCO 2018 and the role of window study. 